New Approach Performs Well for Measuring CKD Quality of Life
Novel composite score is also reliable single-score summary of Kidney Disease Quality of Life-36
Diagnosis & Disease Information
ESA Use for Non-Dialysis CKD Anemia in Decline
Use of erythropoiesis-stimulating agents to treat anemia in patients with non-dialysis-dependent chronic kidney disease has been decreasing since the October 2009 publication of TREAT results.
Hepatitis C Infection May Hasten Chronic Kidney Disease Progression
Patients with both CKD and hepatitis C virus infection are at nearly 2-fold higher risk of end-stage renal disease with those who have CKD only.
Statin Use in Advanced CKD Lowers Death Risk
Researchers report a significant 41% decreased mortality risk among patients with advanced CKD who used statins compared with those who did not.
Low eGFR, Worsening Renal Function Predict Higher Post-PCI Death Risk
Low eGFR and worsening renal function are independently associated with a nearly 3-fold increased mortality risk among patients undergoing percutaneous coronary intervention.
CKD Patients Use Proton Pump Inhibitors Longer
Researchers find that physicians prescribe much longer courses of PPI therapy to patients with vs without CKD, despite the potential nephrotoxic effects.
Higher Caffeine Intake May Decrease Death Risk in CKD
Among individuals with chronic kidney disease, those in the top quartile of daily caffeine consumption had a 25% lower risk of death vs those in the bottom quartile.
Study: Long-Term Darbepoetin Use Safe, Effective in Non-Dialysis CKD
Japanese post-marketing study identified no new safety concerns among patients with non-dialysis chronic kidney disease treated with darbepoetin alfa and followed up for 3 years.
Gastrointestinal Lesions Common in Patients With CKD Anemia
In a Spanish study, endoscopic evaluation of patients with CKD and anemia revealed that 68.2% of patients had at least 1 gastrointestinal lesion.
Febuxostat May Preserve Renal Function in Some CKD Subgroups
Study of patients with CKD stage 3 and asymptomatic hyperuricemia showed that febuoxostat ameliorated the annual decline in eGFR vs placebo in those without proteinuria.
- Loading...
Loading...
Next post in Chronic Kidney Disease (CKD)
Loading... 
Loading...